CD19 and lymphoma: Since the induction of CDC along the classical pathway requires efficient C1q deposition, we investigated whether the EFTAE amino acid substitutions in engineered CD19 antibodies promoted C1q fixation on lymphoma cells and whether this was affected by the antibody fucosylation status (Figure 4A).